Phase II Study Using Thalidomide for the Treatment of ALS

Phase II Study Using Thalidomide for the Treatment of Amyotrophic Lateral Sclerosis

The use of Thalidomide in patients with ALS who have disease progression.

Phase II open labeled trial testing the efficacy of thalidomide for ALS in the setting of disease progression.

Inclusion Criteria:

• Clinically proven ALS
• Disease duration less than or equal to 5 years
• ALSFRS-R score equal to or greater then 30

Exclusion Criteria:

• Patients with known deep venous thrombosis or hyper coagulable state will be excluded
• Patients with FVC less than 80%